{"name":"Navitor Pharmaceuticals, Inc.","slug":"navitor-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQVTllTXRfTlJWVl9SR0tIVUh4QTBUeHpmREgtc0xSWkQ3am9QZXlGUmFGSTAxYWlaYktYNTk3VVBtZlNWQ2RMeWJUclduUVhVUVlYcHVBbVhMWXdZZ1pCWjRrRmJ0NnRBakQwbl9URmdMZ1VMcmNSa0lzLWVndkc5OXBkU0pVVXlsSVRlMXpBMlVoMWtZTEotTWFYSVRtZGpZQzZZWmF3bm5NaW95M0hlYmN2QQ?oc=5","date":"2026-04-07","type":"deal","source":"GuruFocus","summary":"Supernus (SUPN) Acquires Key Assets from Navitor Pharmaceuticals - GuruFocus","headline":"Supernus (SUPN) Acquires Key Assets from Navitor Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQNkRzN0Y5TU00TUF4SnN2T2l6SW5qZ0dkTjFMNGJ2NUVBb01fSFFsdlFjU2owT3B6NmdNVTM1blpvNmpIZ2tOOVFTWGJfNEd0dE5Ud0ttSjdMWk0tRVZ2Yk5CQ0ZETFBLTGp5dWxKbFBkbW1CNlRuOEtHYVN4YkNIN1lKTnZCSHNkYkk0QzJxV0JnbEtMVmNIc3FEVEhSMWxWYTNmd20yOVBnNkQ5WFotTHNQMnVDanJi?oc=5","date":"2026-04-07","type":"pipeline","source":"Stock Titan","summary":"[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event - Stock Titan","headline":"[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPSGpleUFoZ1RLc3FzUmNtWHN2cEVsTnpnRnNOSmQtNWkwSmJOS2M4U24wdXp1Q0hzT0N6aFJaRXdmU2FvU0JmYmg1Z0ZDaUtFUnRSQWZMWXM5OGZFenNZUkNLNUpGd1R6c3R2Rl8yS2FVYmJIbzdIX25ERThnUHNCbGxBczE3VlpnZEE?oc=5","date":"2025-02-20","type":"pipeline","source":"The Pharma Letter","summary":"Depression failure sends Supernus shares downwards - The Pharma Letter","headline":"Depression failure sends Supernus shares downwards","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9jX0ZBM3luZHl5Y2tmU2xldmY2M19maFlHYTVSNUpkQ0JCd1RtMnVUU0dUREJIaXJLWnNJdEdOLWFub2t2NThETmh4djVLM0dMQVpn?oc=5","date":"2025-02-19","type":"trial","source":"FirstWord Pharma","summary":"Supernus' depression candidate fails in mid-stage study - FirstWord Pharma","headline":"Supernus' depression candidate fails in mid-stage study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNUTBFOFJkRUVyelV6cTFwaEV1aDIzYUVZQmFQc2xNZkt1MlFxWUxHd0ZfaWJaVnZDN1hzeXYwaDlfNTBrYXV6a1U3aXU3b1ZTTGVTc2ptZkozakU2NFFkN2Y2cFRFTi1iYjNOdEFnVHNCbzVtczYwRzFqQlpSNTJaT0dYU0I?oc=5","date":"2025-02-19","type":"trial","source":"pharmaphorum","summary":"Supernus reports less than super data for depression drug - pharmaphorum","headline":"Supernus reports less than super data for depression drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOLU1mTkQ2YkRCbDBoUlhFcEV1eVJFSFAxS3Exam9abkk2akhGS3FTSGtHa0JiYXZjS0ZIN3VPYXR4VkVFRlFqQnVYSUN0RS1Va0ZLMDhMc29EaXdINjZjRTVIVXRTa1B0SHcwX013OUFFUk82QXhfdzJSWjNidHJ4WUpQd0JRdTNObnhndlh3T1VHV2pIbXFaSk5ieWdES19vMWM5ZUM2STlpTDRhemN4ZndMdC1zM1h4SzYwM0xFZFNFeF9TalE?oc=5","date":"2025-02-19","type":"trial","source":"Fierce Biotech","summary":"Options shrink for Supernus depression drug candidate after key trial failure - Fierce Biotech","headline":"Options shrink for Supernus depression drug candidate after key trial failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPR2V6SnZnSm5oYXlMY3VzelFoMng3b2szY3p6R0hTZnVkNjVRNTJCbzd2ODEzay16dnVyYzRZUzR2cGpBZHZSeUNZd211SkpXdlVJcGd2aEVfR3IwOVU5cWUwUDBGVXp1ckRNQmpNdjQtZkR6djE0MUw5WmdUUGh5VVc2bXRMbnQ2d2RJdHl5LWEtVXlXQnItWl9yRk83RldHVkQ2d0hR?oc=5","date":"2025-02-19","type":"trial","source":"Pharmaceutical Technology","summary":"Supernus’s stock sinks after depression drug fails trial - Pharmaceutical Technology","headline":"Supernus’s stock sinks after depression drug fails trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9TcWZTV1hpdU11dDdrNEN2MVpOejNUdU85cjlfbF9ad2hrUk41REhPanV3T0x3b05CR1pGYWFDcmd5SWNvVlJhWVBUNVF2cDd4eWY0ci1VbTVjelc2RnFv?oc=5","date":"2024-03-07","type":"trial","source":"Nature","summary":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial | Molecular Psychiatry - Natur","headline":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNX0JGNl9sRzJYb00tVDdnaE9BVUIwZDM0Sm5qOHJWUElZV2FqOXRld1lEdHVFZi1JS0F6QnVOY2h0RVhEUmtLdHhUeTRlTDkyN3cxSml1NW5NQS1tQVdlNnF6VkwyMEpfaGItTFpEdEs5amoxUlBtRkZ1VjlNQ3NfamFfTEpBRS0wWE9iZ2RNV0FLWXJjLXUxYWduTzFscktmaW90V01Fclh3eVc5ZUNSUW9aM05laHFJdms5blFXTnZreHRVRUtlM09ISTBYb0J6ZUJISTJZanJwUE90VVlYaDJ0MGNWMDczNTlZa2V1MHIxRVZZbXE2Nks1VQ?oc=5","date":"2022-05-05","type":"pipeline","source":"PR Newswire","summary":"Totus Medicines Announces Global Pharma Leader Tom Hughes as Board Chair & Creation of Scientific Advisory Board - PR Newswire","headline":"Totus Medicines Announces Global Pharma Leader Tom Hughes as Board Chair & Creation of Scientific Advisory Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPc05mNkh2aEY4LVRRTHZMN1U0cERncTdUUFR2X3pNVEhkNGZZbE5NMzlMRktlcGV5YldoRlZGbjd2Z0M4M1lwX2F0VmRKdXdxOEo2d2kyXzJIUEhFTUExcEdjZ25NcEZfdHRjcDVPOVBfRGd3YkJERzdqRGZ6ekxheVgwYVdIM3BNQnpNYUwtTFFmMDQ?oc=5","date":"2020-09-01","type":"pipeline","source":"drugdiscoverytrends.com","summary":"How Navitor could improve the way you age gracefully - drugdiscoverytrends.com","headline":"How Navitor could improve the way you age gracefully","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNMVAwM2JJT2ZqTDdpODdybE82N201Rm1keXRweEJnNVdud2tyZjU0WTBYUExfWTFCbVNBZzlFYk1PcUhKbmhkVTh0WHduUjg0T3pHU3BIMW1HaHdJNXp3NVZ2bGsxMi0xZFFibWRlMnhJX1FNcjMydUdjX1JUT3ctcng0N1JvQXM4blRlQ29KOVg0SkQxUmJxQzVzUXpVV1lYZzZ3RmJMbXZhMmpDd3JsVFpXVmdneFhrOVRIdWVXM0NVTVdDZndiSnFoSjZBZ1hQTzJMbWhoNU93dktUaHN3TTVLZHlIR1NPZ1RlOVJEOUdlU1lJcldBRnA5WjNwbkFEcjVyR2FTNnV0VlBHQmc?oc=5","date":"2020-04-21","type":"pipeline","source":"globenewswire.com","summary":"Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138 - globenewswire.com","headline":"Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPNXI4T2JteTZtenMxUEZkTEdlYkF0bDQ4NFNkYW1LaUpYQ0Z4NmZJUnE2dnY5TTJSd2xmYWh2S3J1OEFqUXN4ZjZlRi1aM203QzZ2dDZMYTVMbDF0ckJySUJIamhLd3c4ZTc0ZVdfRzFvMFJrZF9jamliT1g4UmhjVjJjaUNwclE?oc=5","date":"2018-07-03","type":"pipeline","source":"statnews.com","summary":"Companies are racing to develop fast-acting depression drugs — but the process is tricky - statnews.com","headline":"Companies are racing to develop fast-acting depression drugs — but the process is tricky","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}